SCHEMBL26501733

SCHEMBL26501733

Cc1ccc(CS(=O)(=O)c2ccc(C(C)C)cc2)nn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.40
BCHE P06276 1/20 0.38
ACHE P22303 1/20 0.38
DRD3 P35462 2/20 0.38
KCNH2 Q12809 2/20 0.38
DRD2 P14416 1/20 0.38
LMNA P02545 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
PKM P14618 1/20 0.37
HPGD P15428 3/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 3/20 0.36
GAA P10253 1/20 0.36
CNR2 P34972 1/20 0.35
TP53 P04637 1/20 0.35
POLB P06746 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
APOBEC3G Q9HC16 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26501736 0.87 ALDH1A1 (0.37) ALDH1A1LMNAHPGDL3MBTL1KDM4E
SCHEMBL26501737 0.87 ALDH1A1 (0.40) ALDH1A1LMNASMN1; SMN2HPGDL3MBTL1
SCHEMBL26501740 0.86 ALDH1A1 (0.35) ALDH1A1LMNAHPGDL3MBTL1KDM4E
SCHEMBL26501738 0.86 TAAR1 (0.37) ALDH1A1LMNAHPGDL3MBTL1KDM4E
SCHEMBL26501709 0.81 BCHE (0.38) ALDH1A1BCHEACHEDRD3KCNH2
SCHEMBL26501742 0.80 CHRNA7 (0.36) ALDH1A1LMNASMN1; SMN2HPGDL3MBTL1
SCHEMBL26501734 0.79 ALDH1A1 (0.46) ALDH1A1BCHEACHEDRD3LMNA
SCHEMBL26501744 0.76 ALDH1A1 (0.32) ALDH1A1LMNAHPGDL3MBTL1MAPT
SCHEMBL26501648 0.71 DHFR (0.47) ALDH1A1BCHEACHELMNASMN1; SMN2
SCHEMBL10180779 0.70 GAA (0.59) ALDH1A1BCHEACHEDRD3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. 2023-10-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230321092-A1 METHODS OF TREATING DISORDERS ASSOCIATED WITH CASTOR HMGCR, GCDH, CYP11A1 ALDH1A1 715/4885BCHE 985/4885ACHE 4173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.